Literature DB >> 15550673

The human polyomavirus, JCV, uses serotonin receptors to infect cells.

Gwendolyn F Elphick1, William Querbes, Joslynn A Jordan, Gretchen V Gee, Sylvia Eash, Kate Manley, Aisling Dugan, Megan Stanifer, Anushree Bhatnagar, Wesley K Kroeze, Bryan L Roth, Walter J Atwood.   

Abstract

The human polyomavirus, JCV, causes the fatal demyelinating disease progressive multifocal leukoencephalopathy in immunocompromised patients. We found that the serotonergic receptor 5HT2AR could act as the cellular receptor for JCV on human glial cells. The 5HT2A receptor antagonists inhibited JCV infection, and monoclonal antibodies directed at 5HT2A receptors blocked infection of glial cells by JCV, but not by SV40. Transfection of 5HT2A receptor-negative HeLa cells with a 5HT2A receptor rescued virus infection, and this infection was blocked by antibody to the 5HT2A receptor. A tagged 5HT2A receptor colocalized with labeled JCV in an endosomal compartment following internalization. Serotonin receptor antagonists may thus be useful in the treatment of progressive multifocal leukoencephalopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550673     DOI: 10.1126/science.1103492

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  157 in total

1.  Hidden in plain view: emergence of progressive multifocal leukoencephalopathy after treatment of CNS toxoplasmosis.

Authors:  Sarah Gheuens; Sarah H Cheeseman; Igor J Koralnik
Journal:  Acta Neurol Belg       Date:  2011-09       Impact factor: 2.396

Review 2.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 3.  Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors:  A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal:  J Neurovirol       Date:  2012-02       Impact factor: 2.643

Review 4.  [Therapeutic monoclonal antibodies in clinical neurology].

Authors:  M Buttmann; H Wiendl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 5.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 6.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

7.  Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.

Authors:  Rebekka Kurmann; Christian Weisstanner; Piotr Kardas; Hans H Hirsch; Roland Wiest; Bernhard Lämmle; Hansjakob Furrer; Renaud Du Pasquier; Claudio L Bassetti; Mathias Sturzenegger; Heinz Krestel
Journal:  J Neurovirol       Date:  2015-04-28       Impact factor: 2.643

8.  High-throughput cell-based screen for chemicals that inhibit infection by simian virus 40 and human polyomaviruses.

Authors:  Edward C Goodwin; Walter J Atwood; Daniel DiMaio
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 9.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

10.  The 50th birthday of progressive multifocal leukoencephalopathy: New insights into pathogenesis.

Authors:  Kenneth L Tyler
Journal:  Ann Neurol       Date:  2008-10       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.